Susan Sorrells1, Sandra Camprubi2, Rhonda Griffin3, Junliang Chen3, Jaume Ayguasanosa2. 1. Grifols Inc., 79 TW Alexander Drive, Bldg 4201, P.O. Box 110526, Research Triangle Park, NC, USA. Electronic address: susan.sorrells@grifols.com. 2. Instituto Grifols S.A., Parc Empresarial Can Joan, Av. De la Generalitat, 152-158, 08174 Sant Cugat del Vallés, Barcelona, Spain. 3. Grifols Inc., 79 TW Alexander Drive, Bldg 4201, P.O. Box 110526, Research Triangle Park, NC, USA.
Abstract
BACKGROUND:Alpha1-antitrypsin deficiency (AATD) is an underdiagnosed genetic disorder that results in early-onset emphysema due to low serum levels of alpha1-proteinase inhibitor (alpha1-PI), leading to increased activity of tissue-damaging neutrophil elastase. Clinical outcomes of AATD may be improved by administering alpha1-PI augmentation therapy. Here, we describe the design of the ongoing Study of ProlAstin-c Randomized Therapy with Alpha-1 augmentation (SPARTA), a phase 3 trial designed to evaluate progression of lung tissue loss in patients with severe AATD receiving human alpha1-PI (Prolastin(®)-C) versusplacebo, using whole-lung computed tomography (CT) densitometry. STUDY DESIGN: SPARTA is a randomized, placebo-controlled trial assessing the efficacy and safety of two separate doses of Prolastin-C (60 and 120 mg/kg) administered weekly over 3 years in patients aged 18-70 years with a diagnosis of AATD and clinical evidence of pulmonary emphysema. The primary measure of efficacy (change from baseline whole-lung 15th percentile lung density [PD15]) will be determined by CT lung densitometry measured at total lung capacity. Secondary efficacy variables will be the evaluation of severe chronic obstructive pulmonary disease exacerbations, as defined by American Thoracic Society/European Respiratory Society criteria, and PD15 of the basal lung region using CT densitometry. Adverse events will be collected and documented. CONCLUSIONS: The SPARTA trial is designed to evaluate the long-term (3-year) efficacy of 2 separate doses of Prolastin-C for the treatment of emphysema in patients with AATD. Protocol number: GTi1201. CLINICAL TRIALS IDENTIFIER: NCT01983241.
RCT Entities:
BACKGROUND:Alpha1-antitrypsin deficiency (AATD) is an underdiagnosed genetic disorder that results in early-onset emphysema due to low serum levels of alpha1-proteinase inhibitor (alpha1-PI), leading to increased activity of tissue-damaging neutrophil elastase. Clinical outcomes of AATD may be improved by administering alpha1-PI augmentation therapy. Here, we describe the design of the ongoing Study of ProlAstin-c Randomized Therapy with Alpha-1 augmentation (SPARTA), a phase 3 trial designed to evaluate progression of lung tissue loss in patients with severe AATD receiving human alpha1-PI (Prolastin(®)-C) versus placebo, using whole-lung computed tomography (CT) densitometry. STUDY DESIGN: SPARTA is a randomized, placebo-controlled trial assessing the efficacy and safety of two separate doses of Prolastin-C (60 and 120 mg/kg) administered weekly over 3 years in patients aged 18-70 years with a diagnosis of AATD and clinical evidence of pulmonary emphysema. The primary measure of efficacy (change from baseline whole-lung 15th percentile lung density [PD15]) will be determined by CT lung densitometry measured at total lung capacity. Secondary efficacy variables will be the evaluation of severe chronic obstructive pulmonary disease exacerbations, as defined by American Thoracic Society/European Respiratory Society criteria, and PD15 of the basal lung region using CT densitometry. Adverse events will be collected and documented. CONCLUSIONS: The SPARTA trial is designed to evaluate the long-term (3-year) efficacy of 2 separate doses of Prolastin-C for the treatment of emphysema in patients with AATD. Protocol number: GTi1201. CLINICAL TRIALS IDENTIFIER: NCT01983241.
Authors: Srinu Tumpara; Beatriz Martinez-Delgado; Gema Gomez-Mariano; Bin Liu; David S DeLuca; Elena Korenbaum; Danny Jonigk; Frank Jugert; Florian M Wurm; Maria J Wurm; Tobias Welte; Sabina Janciauskiene Journal: Front Pharmacol Date: 2020-07-03 Impact factor: 5.810
Authors: Boris M Baranovski; Eyal Ozeri; Galit Shahaf; David E Ochayon; Ronen Schuster; Nofar Bahar; Noa Kalay; Pablo Cal; Mark I Mizrahi; Omer Nisim; Pnina Strauss; Eran Schenker; Eli C Lewis Journal: J Pharmacol Exp Ther Date: 2016-11-07 Impact factor: 4.030
Authors: Ross G Edgar; Mitesh Patel; Susan Bayliss; Diana Crossley; Elizabeth Sapey; Alice M Turner Journal: Int J Chron Obstruct Pulmon Dis Date: 2017-05-02
Authors: Teri-Louise North; Yoav Ben-Shlomo; Cyrus Cooper; Ian J Deary; John Gallacher; Mika Kivimaki; Meena Kumari; Richard M Martin; Alison Pattie; Avan Aihie Sayer; John M Starr; Andrew Wong; Diana Kuh; Santiago Rodriguez; Ian N M Day Journal: J Med Genet Date: 2016-02-01 Impact factor: 6.318